MCM
ABCL icon

MAI Capital Management’s AbCellera Biologics ABCL Stock Holding History

MAI Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-266
Closed -$929 – 2115
2026
Q1 		$929 Hold
266
– – ﹤0.01% 4207
2025
Q4 		$910 Hold
266
– – ﹤0.01% 3658
2025
Q3 		$1.34K Sell
266
-752
-74% -$3.31K ﹤0.01% 3419
2025
Q2 		$3.49K Buy
+1,018
New +$2.53K ﹤0.01% 3219

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

MAI Capital Management's ABCL Position: Q2 2026 in Review

MAI Capital Management sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 266 shares — an estimated $929 sold.

MAI Capital Management first reported a position in ABCL in Q2 2025 and held it in 4 quarters. The position peaked at $3.49K in Q2 2025. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • MAI Capital Management reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 266 AbCellera Biologics shares in Q2 2026, an estimated $929.
  • MAI Capital Management first reported a position in AbCellera Biologics in Q2 2025 and held it in 4 quarters.
  • MAI Capital Management's AbCellera Biologics position peaked at $3.49K in Q2 2025.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.